Skip to main content
. Author manuscript; available in PMC: 2013 Jul 2.
Published in final edited form as: Br J Haematol. 2011 Oct 20;155(4):457–467. doi: 10.1111/j.1365-2141.2011.08882.x

Fig 4.

Fig 4

Lenalidomide therapy alters the cytokine microenvironment. Plasma cytokine levels were measured as described in the methods. Patients were categorized into Complete Remission/Partial Remission (CR/PR) or stable disease (SD) according to clinical criteria. (A) Pre-treatment distribution of cytokines that differed between CR/PR and SD patient groups. The cytokine measurements (pg/ml) for each population are plotted on the x-axis. (B) Distribution of post-treatment (day 8) cytokines that differed between CR/PR and SD patient groups. (C) Distribution of the change of cytokine levels (post-treatment (day 8) – pre-treatment levels) of cytokines between CR/PR and SD/PD patient groups. Prob, estimated probability that the CR/PR cytokine value is lower than the SD/PD cytokine value; 1-Prob, estimated probability that a PR/CR cytokine value exceeds that of the SD/PD cytokine value.